Evommune (EVMN) Short-term Investments (2024 - 2026)

Evommune (EVMN) has 3 years of Short-term Investments data on file, last reported at $163.1 million in Q1 2026.

• Short-term Investments for Q1 2026 came in at $163.1 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $163.1 million (changed N/A YoY), and the FY2025 annual result was $105.1 million, up 88.47% from the prior year.
• Short-term Investments rose to $163.1 million in Q1 2026 per EVMN's latest filing, from $105.1 million in the prior quarter.
• Over five years, Short-term Investments peaked at $163.1 million in Q1 2026 and troughed at $49.2 million in Q3 2025.
• A 3-year average of $93.3 million and a median of $80.5 million in 2024 frame the typical range for Short-term Investments.
• On a YoY basis, Short-term Investments climbed as much as 88.47% in 2025 and fell as far as 88.47% in 2025.
• A 3-year view of Short-term Investments shows it stood at $55.8 million in 2024, then soared by 88.47% to $105.1 million in 2025, then surged by 55.17% to $163.1 million in 2026.
• Business Quant data shows EVMN's Short-term Investments at $163.1 million in Q1 2026, $105.1 million in Q4 2025, and $49.2 million in Q3 2025.